Foundation Medicine has received FDA approval for a liquid biopsy test that can detect mutations in multiple cancers. The test, known as Foundationone Liquid CDx, is expected to broaden access to early and less invasive cancer detection. The approval is part of a trend of advancements in liquid biopsy tests, with other companies, such as Guardant, also receiving FDA nods for similar tests.